Prognostic role of multidrug resistance‑associated protein 1 expression and platelet count in operable non‑small cell lung cancer

Fang,Linming; Sheng,Huaying; Wan,Danying; Zhu,Chihong; Jiang,Ruibin; Sun,Xiaojiang; Feng,Jianguo

doi:10.3892/ol.2018.8763

Prognostic role of multidrug resistance‑associated protein 1 expression and platelet count in operable non‑small cell lung cancer

Authors:
- Linming Fang
- Huaying Sheng
- Danying Wan
- Chihong Zhu
- Ruibin Jiang
- Xiaojiang Sun
- Jianguo Feng
View Affiliations

Affiliations: Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: May 22, 2018 https://doi.org/10.3892/ol.2018.8763
Pages: 1123-1132

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The overall survival rate of patients with non‑small cell lung cancer (NSCLC) following resection remains poor due to the high rates of recurrence and metastasis. The investigation of novel biomarkers is clinically necessary to improve treatment strategies. Multidrug resistance‑associated protein 1 (MRP1) and platelet count are linked to a poor prognosis in various types of cancer. However, it is unknown whether MRP1 or platelet count is a suitable prognostic indicator of NSCLC. In the present study, 427 patients with operable NSCLC were enlisted. The association of MRP1 expression and platelet count with clinical pathological factors and patient outcome was evaluated. MRP1 expression was found to be significantly associated with sex, histological type and tumor differentiation, while platelet count was significantly associated with smoking behavior, histological type and clinical stage. Platelet count was significantly higher in patients with negative MRP1 expression than in those with positive MRP1 expression. Survival analysis indicated that there was no association between MRP1 expression and disease‑free survival (DFS) or overall survival (OS) time. In the patients with no lymph node metastasis, the OS time was significantly longer in patients with positive MRP1 expression than in those with negative expression. However, in the patients with lymph node metastasis, the DFS time was significantly shorter in patients with positive MRP1 expression than in those with negative expression. There was an association between the platelet count and DFS and OS times, which were significantly longer in patients with a normal platelet count than in those with thrombocytosis. In conclusion, MRP1 expression and platelet count are valuable independent prognostic biomarkers for survival in operable NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C and Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI
3	Reck M, Popat S, Reinmuth N, de Ruysscher D, Kerr KM and Peters S; ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl 3): iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
4	Vallières E, Shepherd FA, Crowley J, van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions: The IASLC Lung Cancer Staging Project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac. 4:1049–1059. 2009. View Article : Google Scholar
5	Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ and Scheper RJ: Tissue distribution of the multidrug resistance protein. Am J Pathol. 148:1237–1247. 1996.PubMed/NCBI
6	Schinkel AH and Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev. 55:3–29. 2003. View Article : Google Scholar : PubMed/NCBI
7	Cole SP: Targeting multidrug resistance protein 1 (MRP1, ABCC1): Past, present, and future. Ann Rev Pharmacol Toxicol. 54:95–117. 2014. View Article : Google Scholar
8	Li A, Song J, Lai Q, Liu B, Wang H, Xu Y, Feng X, Sun X and Du Z: Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line. Int J Exp Pathol. 97:412–421. 2016. View Article : Google Scholar : PubMed/NCBI
9	Chen JJ, Liu SP, Zhao J, Wang SC, Liu TJ and Li X: Effects of a novel photoactivated photosensitizer on MDR1 over-expressing human breast cancer cells. J Photochem Photobiol B Biol. 171:67–74. 2017. View Article : Google Scholar
10	Melguizo C, Prados J, Luque R, Ortiz R, Caba O, Alvarez PJ, Gonzalez B and Aranega A: Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure. Int J Mol Sci. 13:16624–16635. 2012. View Article : Google Scholar : PubMed/NCBI
11	Luque R, Gonzalez Flores E, Delgado JR, Melguizo C, Prados JC, Gonzalez Astorga B, Ortiz R, Sánchez Toro C, Valdivia J and Aránega A: MDR1 gene expression in peripheral blood as a marker of treatment response in lung cancer. J Clin Oncol. 30:962012. View Article : Google Scholar
12	Wu DD, Zhang JX, Li J and Dong WG: Lack of association of the MDR1 C3435T polymorphism with susceptibility to gastric cancer and peptic ulcer: A systemic review and meta-analysis. Asian Pac J Cancer Prev. 15:3021–3027. 2014. View Article : Google Scholar : PubMed/NCBI
13	Qiao W, Wang T, Zhang L, Tang Q, Wang D and Sun H: Association between single genetic polymorphisms of MDR1 gene and gastric cancer susceptibility in Chinese. Med Oncol. 30:6432013. View Article : Google Scholar : PubMed/NCBI
14	Bambace NM and Holmes CE: The platelet contribution to cancer progression. J Thromb Haemost. 9:237–249. 2011. View Article : Google Scholar : PubMed/NCBI
15	Goubran HA, Stakiw J, Radosevic M and Burnouf T: Platelet-cancer interactions. Semin Thromb Hemost. 40:296–305. 2014. View Article : Google Scholar : PubMed/NCBI
16	Li FX, Wei LJ, Zhang H, Li SX and Liu JT: Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer. Asian Pac J Cancer Prev. 15:6511–6517. 2014. View Article : Google Scholar : PubMed/NCBI
17	Chadha AS, Kocak-Uzel E, Das P, Minsky BD, Delclos ME, Mahmood U, Guha S, Ahmad M, Varadhachary GR and Javle M: et alParaneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 54:971–978. 2015. View Article : Google Scholar : PubMed/NCBI
18	Feng Z, Wen H, Bi R, Duan Y, Yang W and Wu X: Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. BMC Cancer. 16:432016. View Article : Google Scholar : PubMed/NCBI
19	Josa V, Krzystanek M, Eklund AC, Salamon F, Zarand A, Szallasi Z and Baranyai Z: Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer. Int J Surg. 18:1–6. 2015. View Article : Google Scholar : PubMed/NCBI
20	Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M and Tausch C: et alImpact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 89:1098–1106. 2003. View Article : Google Scholar : PubMed/NCBI
21	Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ and van Schil PE: et alInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
22	Berger W, Elbling L, Hauptmann E and Micksche M: Expression of the multidrug resistanceassociated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 1997:. 73:84–93. 1997.
23	Young LC, Campling BG, Voskoglou-Nomikos T, Cole SP, Deeley RG and Gerlach JH: Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response. Clin Cancer Res. 5:673–680. 1999.PubMed/NCBI
24	Young LC, Campling BG, Cole SP, Deeley RG and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 7:1798–1804. 2001.PubMed/NCBI
25	Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K and Ogata T: et alExpression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer. 72:550–554. 1995. View Article : Google Scholar : PubMed/NCBI
26	Oshika Y, Nakamura M, Tokunaga T, Fukushima Y, Abe Y, Ozeki Y, Yamazaki H, Tamaoki N and Ueyama Y: Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol. 11:1059–1063. 1998.PubMed/NCBI
27	Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsur A and Micksche M: Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J Cancer Res Clin Oncol. 131:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
28	Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M and Ochiai A: Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 10:1691–1697. 2004. View Article : Google Scholar : PubMed/NCBI
29	Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, André F, Brambilla E, Stahel R, Pignon JP and Soria JC: et alMultidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res. 13:3892–3898. 2007. View Article : Google Scholar : PubMed/NCBI
30	Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1029–1039. 1995.PubMed/NCBI
31	Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD and Wallace JL: Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA. 102:216–220. 2005. View Article : Google Scholar : PubMed/NCBI
32	Lewalle JM, Castronovo V, Goffinet G and Foidart JM: Malignant cell attachment to endothelium of ex vivo perfused human umbilical vein. Modulation by platelets, plasma and fibronectin. Thromb Res. 62:287–298. 1991. View Article : Google Scholar : PubMed/NCBI
33	Shim M, Song C, Park S, Choi SK, Cho YM, Kim CS and Ahn H: Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 141:2213–2220. 2015. View Article : Google Scholar : PubMed/NCBI
34	Jurasz P, Alonso-Escolano D and Radomski MW: Platelet-cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 143:819–826. 2004. View Article : Google Scholar : PubMed/NCBI
35	Bobek V and Kovarík J: Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother. 58:213–219. 2004. View Article : Google Scholar : PubMed/NCBI
36	Blom JW, Osanto S and Rosendaal FR: The risk of a venous thrombotic event in lung cancer patients: Higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2:1760–1765. 2004. View Article : Google Scholar : PubMed/NCBI
37	Barcala JG, Portal JA, Carmona MJ and González CM: Exposure to environmental contaminants and respiratory disease. Spotlight on the year 2009. Arch Bronconeumol. 46(Suppl 1): S17–S20. 2010.(In Spanish).